Literature DB >> 27372069

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Giancarlo Pruneri1,2, Kathryn P Gray3,4, Andrea Vingiani5,6, Giuseppe Viale5,6, Giuseppe Curigliano7, Carmen Criscitiello7, István Láng8, Thomas Ruhstaller9,10, Lorenzo Gianni11, Aron Goldhirsch12, Roswitha Kammler13, Karen N Price3,14, Giuseppe Cancello15, Elisabetta Munzone15, Richard D Gelber16,3,4,14,17, Meredith M Regan16,3,17, Marco Colleoni15.   

Abstract

The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral 'metronomic' cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (< 1 % of ER and PgR immunoreactivity and absence of HER2 overexpression or amplification). Mononuclear cells were evaluated in the stromal area within the borders of the invasive tumor. The primary endpoint was breast cancer-free interval (BCFI). Cox proportional hazards regression model assessed the association of BCFI and secondary endpoints with TILs score. In the 647 tumor samples, the median percentage of TILs was 18 % (IQR = 8-40 %), with 18 % having TILs ≥ 50 % (lymphocyte-predominant breast cancer, LPBC). At a median follow-up of 6.9 years, TILs were associated with better prognosis. For every 10 % increase of TILs, BCFI risk reduction was 13 % (HR 0.87, 95 % CI 0.79-0.95,P = 0.003). DFS, DRFI, and OS risk reductions were 11 % (P = 0.005), 16 % (P = 0.003), and 17 % (P < 0.001), respectively. Multivariable analysis confirmed the independent prognostic value of TILs. No significant TILs-by-treatment interaction was observed (P = 0.39) for associations of TILs with BCFI, although patients with LPBC receiving CM-maintenance had a greater breast cancer risk reduction (HR 0.64,95 % CI 0.23-1.78) than those with non-LPBC (TILs < 50 %) (HR 0.96, 95 % CI 0.67-1.40). TILs score is a potent prognostic factor in patients with TNBC. Low-dose chemotherapy confers a greater (not statistically significant) clinical benefit in patients with LPBC.

Entities:  

Keywords:  Breast cancer; Low-dose maintenance chemotherapy; Prognosis; Triple negative; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27372069      PMCID: PMC4977583          DOI: 10.1007/s10549-016-3863-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.

Authors:  Laura Orlando; Anna Cardillo; Andrea Rocca; Alessandra Balduzzi; Raffaella Ghisini; Giulia Peruzzotti; Aron Goldhirsch; Claudia D'Alessandro; Saverio Cinieri; Lorenzo Preda; Marco Colleoni
Journal:  Anticancer Drugs       Date:  2006-09       Impact factor: 2.248

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

3.  Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

Authors:  Marco Colleoni; Kathryn P Gray; Shari Gelber; István Láng; Beat Thürlimann; Lorenzo Gianni; Ehtesham A Abdi; Henry L Gomez; Barbro K Linderholm; Fabio Puglisi; Carlo Tondini; Elena Kralidis; Alexandru Eniu; Katia Cagossi; Daniel Rauch; Jacquie Chirgwin; Richard D Gelber; Meredith M Regan; Alan S Coates; Karen N Price; Giuseppe Viale; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

4.  Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Authors:  Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

7.  Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.

Authors:  Miki Tongu; Nanae Harashima; Hiroyuki Monma; Touko Inao; Takaya Yamada; Hideyuki Kawauchi; Mamoru Harada
Journal:  Cancer Immunol Immunother       Date:  2012-08-25       Impact factor: 6.968

8.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Authors:  Yuting Ma; Sandy Adjemian; Stephen R Mattarollo; Takahiro Yamazaki; Laetitia Aymeric; Heng Yang; João Paulo Portela Catani; Dalil Hannani; Helene Duret; Kim Steegh; Isabelle Martins; Frederic Schlemmer; Mickaël Michaud; Oliver Kepp; Abdul Qader Sukkurwala; Laurie Menger; Erika Vacchelli; Nathalie Droin; Lorenzo Galluzzi; Roman Krzysiek; Siamon Gordon; Philip R Taylor; Peter Van Endert; Eric Solary; Mark J Smyth; Laurence Zitvogel; Guido Kroemer
Journal:  Immunity       Date:  2013-04-04       Impact factor: 31.745

Review 9.  Clinical overview of metronomic chemotherapy in breast cancer.

Authors:  Elisabetta Munzone; Marco Colleoni
Journal:  Nat Rev Clin Oncol       Date:  2015-08-04       Impact factor: 66.675

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more
  28 in total

1.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 2.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

3.  Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.

Authors:  Malgorzata Banys-Paluchowski; Eugen Ruckhäberle; Florian Schütz; Natalia Krawczyk; Tanja Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-02       Impact factor: 2.915

4.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors:  Sherene Loi; Damien Drubay; Sylvia Adams; Giancarlo Pruneri; Prudence A Francis; Magali Lacroix-Triki; Heikki Joensuu; Maria Vittoria Dieci; Sunil Badve; Sandra Demaria; Robert Gray; Elisabetta Munzone; Jerome Lemonnier; Christos Sotiriou; Martine J Piccart; Pirkko-Liisa Kellokumpu-Lehtinen; Andrea Vingiani; Kathryn Gray; Fabrice Andre; Carsten Denkert; Roberto Salgado; Stefan Michiels
Journal:  J Clin Oncol       Date:  2019-01-16       Impact factor: 44.544

5.  Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy.

Authors:  Sumi Yun; Jiwon Koh; Soo Kyung Nam; Yoonjin Kwak; Sang-Hoon Ahn; Joong Do Park; Hyung-Ho Kim; Woo Ho Kim; Hye Seung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-08-12       Impact factor: 6.968

6.  An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.

Authors:  Balazs Acs; David L Rimm; Yalai Bai; Kimberly Cole; Sandra Martinez-Morilla; Fahad Shabbir Ahmed; Jon Zugazagoitia; Johan Staaf; Ana Bosch; Anna Ehinger; Emma Nimeus; Johan Hartman
Journal:  Clin Cancer Res       Date:  2021-06-04       Impact factor: 12.531

7.  VWCE as a potential biomarker associated with immune infiltrates in breast cancer.

Authors:  Qin Huo; Zhenwei Li; Siqi Chen; Juan Wang; Jiaying Li; Ni Xie
Journal:  Cancer Cell Int       Date:  2021-05-21       Impact factor: 5.722

Review 8.  Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.

Authors:  Lironne Wein; Peter Savas; Stephen J Luen; Balaji Virassamy; Roberto Salgado; Sherene Loi
Journal:  Front Oncol       Date:  2017-08-03       Impact factor: 6.244

9.  Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.

Authors:  Anita Grigoriadis; Patrycja Gazinska; Trupti Pai; Sheeba Irhsad; Yin Wu; Rosemary Millis; Kalnisha Naidoo; Julie Owen; Cheryl E Gillett; Andrew Tutt; Anthonius Cc Coolen; Sarah E Pinder
Journal:  J Pathol Clin Res       Date:  2018-01-08

Review 10.  Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

Authors:  M E Cazzaniga; L Cortesi; A Ferzi; L Scaltriti; F Cicchiello; M Ciccarese; S Della Torre; F Villa; M Giordano; C Verusio; M Nicolini; A R Gambaro; L Zanlorenzi; E Biraghi; E Casini; L Legramandi; E Rulli
Journal:  Int J Breast Cancer       Date:  2017-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.